Anne K Monroe1, Adrian S Dobs. 1. Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Maryland, USA.
Abstract
PURPOSE OF REVIEW: To review recent data concerning the relationship between endogenous testosterone and lipids as well as testosterone replacement therapy and lipids. To describe the effects of sex hormones on cardiovascular disease (CVD) that may act via serum lipids. RECENT FINDINGS: Low endogenous testosterone is associated with high low-density lipoprotein and low high-density lipoprotein in both cross-sectional and prospective observational studies. Exogenous testosterone administration is associated with decreased high-density lipoprotein coupled with beneficial decreases in low-density lipoprotein and total cholesterol. The overall impact of testosterone administration on CVD is still unclear, with mixed safety results from recent randomized controlled trials. SUMMARY: There may be CVD risk reduction benefits, including an improved lipid profile, from testosterone administration in hypogonadal men. The overall effect of testosterone on CVD risk has not been definitively determined.
PURPOSE OF REVIEW: To review recent data concerning the relationship between endogenous testosterone and lipids as well as testosterone replacement therapy and lipids. To describe the effects of sex hormones on cardiovascular disease (CVD) that may act via serum lipids. RECENT FINDINGS: Low endogenous testosterone is associated with high low-density lipoprotein and low high-density lipoprotein in both cross-sectional and prospective observational studies. Exogenous testosterone administration is associated with decreased high-density lipoprotein coupled with beneficial decreases in low-density lipoprotein and total cholesterol. The overall impact of testosterone administration on CVD is still unclear, with mixed safety results from recent randomized controlled trials. SUMMARY: There may be CVD risk reduction benefits, including an improved lipid profile, from testosterone administration in hypogonadal men. The overall effect of testosterone on CVD risk has not been definitively determined.
Authors: Pi-I D Lin; Andres Cardenas; Russ Hauser; Diane R Gold; Ken P Kleinman; Marie-France Hivert; Abby F Fleisch; Antonia M Calafat; Thomas F Webster; Edward S Horton; Emily Oken Journal: Environ Int Date: 2019-05-28 Impact factor: 9.621
Authors: L C Macleod; L J Chery; E Y C Hu; S B Zeliadt; S K Holt; D W Lin; M P Porter; J L Gore; J L Wright Journal: Prostate Cancer Prostatic Dis Date: 2015-03-31 Impact factor: 5.554
Authors: Colleen M Makey; Michael D McClean; Lewis E Braverman; Elizabeth N Pearce; Andreas Sjödin; Janice Weinberg; Thomas F Webster Journal: Reprod Toxicol Date: 2016-04-14 Impact factor: 3.143
Authors: Fiona Yuen; Arthi Thirumalai; Frances A Fernando; Ronald S Swerdloff; Peter Y Liu; Youngju Pak; Laura Hull; Rachelle Bross; Diana L Blithe; Jill E Long; Stephanie T Page; Christina Wang Journal: Andrology Date: 2021-05-22 Impact factor: 4.456
Authors: P M Willemse; J Burggraaf; N A T Hamdy; N I Weijl; C Y Vossen; L van Wulften; A Q M J van Steijn-van Tol; F R Rosendaal; S Osanto Journal: Br J Cancer Date: 2013-05-09 Impact factor: 7.640